Daily Newsletter

19 March 2024

Daily Newsletter

19 March 2024

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.

Vishnu Priyan March 19 2024

Bristol Myers Squibb (BMS) has concluded the acquisition of biopharmaceutical company Karuna Therapeutics for $14bn in cash.

The transaction was finalised following a definitive agreement signed by the companies in December 2023. Karuna now becomes a wholly owned BMS subsidiary.

The deal will boost BMS's neuroscience portfolio.

BMS has acquired Karuna's lead asset, KarXT (xanomeline-trospium), along with its early-stage and pre-clinical pipeline.

KarXT is an antipsychotic with a unique mechanism of action and a promising efficacy and safety profile.

The US Food and Drug Administration (FDA) recently accepted a new drug application for KarXT for the treatment of adults with schizophrenia, with an approval decision anticipated on 26 September 2025 under the Prescription Drug User Fee Act.

KarXT is also undergoing registrational trials as an adjunctive therapy for schizophrenia and for treating psychosis in Alzheimer's disease patients.

Its potential for further indications such as bipolar 1 disorder and agitation in Alzheimer's disease is being explored.

Financial advisory services for the deal were provided to BMS by Gordon Dyal and Citi, with Covington & Burling offering legal counsel.

Goldman Sachs acted as exclusive financial adviser to Karuna, with Simpson Thacher & Bartlett providing legal counsel.

Bristol Myers Squibb CEO Chris Boerner stated: “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb.

“Importantly, this transaction aligns with our commitment to strengthening BMS’s growth profile in the latter half of the decade and beyond. We look forward to working with Karuna’s talented team to bring KarXT to patients with schizophrenia later this year.”

The new development comes after the FDA’s committee voted eight to three to approve BMS and 2seventy bio’s Abecma to treat relapsed or refractory multiple myeloma.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.